Seraxis Growth Leads to Expansion and a Complex Move to New Facilities

Published on :

After more than a year of searching and planning, Seraxis found a new home in Montgomery County. With the assistance of experienced life sciences logistics company BaneBio, Seraxis was able to seamlessly move into its new facility earlier this year without interrupting its plans to scale and guide its lead cell therapy into the clinic.

Akan Biosciences, Intelligent Fusion Technology, and Seraxis Graduate from Montgomery County’s Business Incubator Program in Germantown

Germantown Innovation Center at PIC MC
Published on :

Three portfolio companies have graduated from the Germantown Innovation Center (GIC), Montgomery County’s business incubator program. The County’s incubator program started in 1999 to foster the growth and development of young technology companies. Akan Biosciences, Intelligent Fusion Technology and Seraxis are the three County-based companies graduating from the program this spring.

GIC Incubates Rising Stars in Maryland’s Life Sciences Ecosystem

Published on :

The Germantown Innovation Center is home to some of Maryland’s fastest-rising stars in the life sciences ecosystem. Multiple startups found a home in the Montgomery County incubator and benefit from the lab space and the strategic access to federal agencies, nearby thought leadership, and on-campus workforce access.

Seraxis Eyes the Clinic Following $40 Million Capital Raise

Seraxis cell therapy replaces damaged or lost insulin-producing pancreatic cells
Published on :

Seraxis, which is currently located at the Pinkney Innovation Complex for Science & Technology at Montgomery College (PIC MC) in the County-owned Germantown Innovation Center is developing its lead therapy, SR-01, to eliminate the need for type 1 diabetes patients to inject insulin. SR-01 is a revolutionary therapy that could impact more than 4.5 million people in the world.

Akan Biosciences Announces FDA Acceptance of IND Application for StroMel™; in Osteoarthritis of Knee

Published on :

StroMel™ is a proprietary adipose-derived Stromal Vascular Fraction (SVF) product. StroMel™ will be frozen and stored allowing multiple administrations with each lot. Although the current IND is for autologous administration, Akan is planning to explore allogeneic applications as well.